Linked Life Data

1967063

Source:http://linkedlifedata.com/resource/pubmed/id/1967063

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-10-26
pubmed:abstractText
The sera of 33 patients who received interleukin-2 and lymphokine activated killer (IL-2/LAK) cells as therapy for advanced neoplasms were assayed for the presence of islet cell antibodies and insulin autoantibodies both prior to and following therapy. All sera were negative for islet cell antibody in all of these patients. However, 4 patients developed insulin autoantibody levels considered to be positive following IL-2/LAK cell therapy. In the entire group, the percent binding and counts displaced in the insulin autoantibody assay following therapy was significantly increased above the levels obtained prior to therapy. This is the first demonstration in non-diabetic humans that exogenous IL-2 in the absence of insulin treatment results in significant augmentation of insulin autoantibodies. These findings suggest that in non-diabetic individuals the B lymphocyte repertoire includes clones autoreactive to insulin.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0141-2760
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-93
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.
pubmed:affiliation
Department of Medicine, University of Washington, Seattle 98195.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't